Bio-MAX Institute, Seoul National University, Seoul, South Korea.
Department of Electrical and Computer Engineering, Seoul National University, Seoul, South Korea.
Front Immunol. 2021 May 19;12:660298. doi: 10.3389/fimmu.2021.660298. eCollection 2021.
In addition to SARS-CoV-2 and its variants, emerging viruses that cause respiratory viral infections will continue to arise. Increasing evidence suggests a delayed, possibly suppressed, type 1 interferon (IFN-I) response occurs early during COVID-19 and other viral respiratory infections such as SARS and MERS. These observations prompt considering IFN-β as a prophylactic or early intervention for respiratory viral infections. A rationale for developing and testing intranasal interferon beta (IFN-β) as an immediately available intervention for new respiratory viral infections that will arise unexpectedly in the future is presented and supported by basic and clinical trial observations. IFN-β prophylaxis could limit the spread and consequences of an emerging respiratory viral infection in at-risk individuals while specific vaccines are being developed.
除了 SARS-CoV-2 及其变体，引起呼吸道病毒感染的新兴病毒将继续出现。越来越多的证据表明，在 COVID-19 和其他病毒性呼吸道感染（如 SARS 和 MERS）期间，I 型干扰素（IFN-I）的反应会延迟，甚至受到抑制。这些观察结果促使人们考虑将 IFN-β 作为预防或早期干预呼吸道病毒感染的手段。本文提出了一种理由，即开发和测试鼻内干扰素-β（IFN-β）作为一种针对未来可能意外出现的新呼吸道病毒感染的即时可用干预措施，这一理由得到了基础和临床试验观察的支持。IFN-β 预防措施可以限制在高危人群中出现的新兴呼吸道病毒感染的传播和后果，同时正在开发特定疫苗。
